Although recent reports suggest the utility of biomarkers such as L-FABP, TNFR2, and Kim-1 [33–35] for early renal failure detection, pathological evaluation based on renal risk prediction is necessary to understand the association between pathophysiological change and biomarkers, because, to our knowledge, there are no definite clinical signs or positive biomarkers that accurately predict presence of nodular lesions, exudative lesions, or mesangiolysis. The gene discussed is FABP1; the disease is kidney failure.